Dapagliflozin Demonstrates Sustained Cardiovascular Benefits in Long-Term Diabetes Study
Key Insights
A 4-year follow-up study shows dapagliflozin maintains a 30% improvement in coronary flow reserve in patients with type 2 diabetes (search) and stable coronary artery disease (search).
The SGLT2 (search) inhibitor significantly reduced epicardial adipose tissue thickness by 29% and reversed cardiac fibrosis (search) in diabetic heart failure patients with preserved ejection fraction.
Clinical trials demonstrate dapagliflozin's disease-modifying potential beyond symptom management, with improvements in cardiac structure and metabolic parameters sustained over extended treatment periods.
A comprehensive 4-year follow-up analysis of the DAPAHEART trial has revealed that dapagliflozin, a sodium-glucose cotransporter-2 (search) (SGLT2 (search)) inhibitor, provides sustained cardiovascular benefits in patients with type 2 diabetes (search) and stable coronary artery disease (search). The findings, published in Cardiovascular Diabetology, demonstrate the drug's ability to maintain significant improvements in coronary microvascular function while reducing harmful cardiac tissue changes.
Sustained Coronary Flow Reserve Improvements
The long-term analysis of 9 patients showed that dapagliflozin maintained a remarkable 34.4% increase in coronary flow reserve (CFR) after 4 years of treatment, rising from 2.15 ± 0.19 at baseline to 2.85 ± 0.26 (p = 0.001). This improvement represents the heart's enhanced ability to increase blood flow during periods of increased demand, such as physical exercise.
Patients originally randomized to dapagliflozin maintained their initial 30% CFR improvement throughout the 4-year period, while those who switched from placebo to dapagliflozin after 4 weeks experienced a significant CFR increase from 1.96 ± 0.09 to 2.43 ± 0.15 (p = 0.007). This pattern strongly supports a causal relationship between dapagliflozin treatment and coronary microvascular improvements.
Epicardial Adipose Tissue Reduction
The study documented a significant 29% reduction in epicardial adipose tissue (EAT) thickness across all patients (from 0.62 ± 0.18 cm at baseline to 0.44 ± 0.11 cm at 4 years; p = 0.03). This reduction is particularly important because EAT alterations have been linked to coronary microvascular dysfunction and inflammation.
Notably, researchers found no significant correlation between body mass index reduction and changes in EAT thickness (R² = 0.0662; p = 0.5), suggesting a weight-independent effect of dapagliflozin on this cardiac fat depot. Even patients who initiated GLP-1 receptor agonists during follow-up showed no greater EAT reduction compared to those who didn't, indicating SGLT2 (search) inhibitors played the predominant role in this beneficial effect.
Cardiac Fibrosis Reversal in Heart Failure
Complementing the DAPAHEART findings, a separate multicentre, double-blind, placebo-controlled trial of 100 patients with heart failure with preserved ejection fraction (search) (HFpEF) and type 2 diabetes (search) demonstrated dapagliflozin's ability to reverse myocardial fibrosis. After 12 months of treatment with dapagliflozin 10 mg daily, patients showed significantly greater reduction in myocardial fibrosis, with a mean extracellular volume fraction change of −3.5% (95% CI: −4.2–−2.8) versus −0.8% (95% CI: −1.3–−0.4) in the placebo group (p < 0.001).
The HFpEF study also revealed improvements in left ventricular mass index (−8.2 g/m² vs. −2.1 g/m²; p=0.002), HbA1c levels (−1.2% vs. −0.4%; p=0.01), and 6-minute walk test performance (+45 m vs. +10 m; p=0.01) compared to placebo.
Mechanistic Insights and Clinical Implications
The sustained improvements in CFR appear to result from dapagliflozin's effect on myocardial blood flow efficiency. The 4-year data showed a significant reduction in myocardial blood flow at rest (from 1.16 ± 0.06 to 0.88 ± 0.07 mL/min/g; p = 0.008) while stress blood flow remained stable, indicating enhanced perfusion efficiency.
Researchers propose that the reduction in EAT thickness mitigates local inflammatory responses, thereby improving coronary perfusion. The restoration of EAT's protective function may contribute to the observed CFR improvements by reducing the inflammatory burden on coronary arteries and allowing for better vasodilation during stress conditions.
Long-Term Safety and Efficacy Profile
Throughout the 4-year follow-up period, patients maintained stable myocardial mechano-energetic efficiency (MEEi), a measure of cardiac performance that assesses the heart's efficiency in converting metabolic energy into mechanical work. While no significant increase was observed, the preservation of MEEi is particularly important in patients with type 2 diabetes (search), where cardiac energetic efficiency is frequently impaired due to insulin resistance.
The study's design strength was enhanced by the fact that patients originally assigned to placebo who later received dapagliflozin showed similar improvements, providing internal validation and reinforcing the causal relationship between the drug and observed benefits.
Clinical Practice Implications
These findings support the inclusion of SGLT2 (search) inhibitors as part of guideline-directed medical therapy for patients with type 2 diabetes (search) and cardiovascular disease, not only for symptom management but potentially for altering the disease course itself. The data suggest meaningful benefits across structural, metabolic, and functional domains that persist over extended treatment periods.
The research demonstrates that dapagliflozin's cardiovascular benefits extend beyond the well-established reductions in heart failure hospitalizations and cardiovascular mortality shown in previous outcome trials. The drug appears to provide disease-modifying effects by addressing underlying pathophysiological mechanisms including myocardial fibrosis and epicardial adipose tissue dysfunction.